Navigation Links
OGI's investment in cytognomix contributes to the Shannon Human Splicing Pipeline's success
Date:4/29/2013

TORONTO, ON, April 29, 2013 - Ontario Genomics Institute (OGI) congratulates Cytognomix on the success of the Shannon Human Splicing Pipeline, which was recently purchased by the National Cancer Institute (NCI) in the U.S. In 2009, OGI invested in Cytognomix through its Pre-commercialization Business Development Fund (PBDF).

Understanding the wealth of data generated by next-generation sequencing is essential to determining which mutations are clinically significant. Cytognomix's Shannon pipeline assesses the millions of variants of unknown significance detected in cancer genetic testing by predicting mRNA splicing abnormalities. This technology improves accuracy and ease of data interpretation, saving time and reducing mistakes.

Investigators at NCI are using the Shannon pipeline to evaluate somatic and germline variants observed in tumor genome next generation sequences for their potential effects on splicing. According to Dr. Mike Nickerson, Cancer and Inflammation Program, NCI, the analytic tool is being applied to evaluate a variety of variants which can be difficult to interpret in terms of their effects on protein function. Analysis of variants for potential effects on splicing provides a tool to distinguish deleterious mutations from passenger variants and generates hypotheses that can be experimentally evaluated using PCR of reverse-transcribed tumor RNA.

"Cytognomix's Shannon pipeline is resolving significant data interpretation issues in cancer research," said Mark Poznansky, CEO, OGI. "It is rewarding to see the companies we invest in succeed and grow. OGI's investment provided Cytognomix with early stage funding, which allowed them to take important next steps toward bringing their products to market."

According to Peter Rogan, CEO of Cytognomix, "Interpreting gene variants of unknown clinical significance is one of the most important challenges in human genomics. While much effort has been focused on gathering existing knowledge about published variants in databases, our Shannon pipeline discovers previously unrecognized functions of non-coding variants. Cytognomix's mutation analysis software products have been validated in numerous peer-reviewed journal publications. We are pleased that the NCI has chosen the Shannon mRNA splicing mutation pipeline to accelerate their understanding of various forms of cancer."

OGI's PBDF program has invested in opportunities based in genomics, proteomics or associated technologies that fall in the proof-of-principle (validation) phase of research and that have the short-term potential to secure a significant next step towards the marketplace. Previous recipients have included Ontario universities, research institutes and companies.


'/>"/>

Contact: Christine Beyaert
cbeyaert@ontariogenomics.ca
416-673-6597
Ontario Genomics Institute
Source:Eurekalert

Related biology news :

1. IU biologists offer clearer picture of how protein machine systems tweak gene expression
2. Microbiologists can now measure extremely slow life
3. American Society of Plant Biologists honors early career women scientists
4. Interventional radiologists see significant symptom relief in MS patients
5. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
6. Penn biologists identify a key enzyme involved in protecting nerves from degeneration
7. University of Toronto biologists predict extinction for organisms with poor quality genes
8. UC Riverside plant cell biologist receives top scientific honor
9. Biologists turn back the clock to understand evolution of sex differences
10. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
11. Anthropologist finds explanation for hominin brain evolution in famous fossil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2019)... (PRWEB) , ... January 23, 2019 , ... ... that it has received a Notice of Allowance from the United States Patent ... filed by its affiliate company, DNA Medicine Institute (DMI). This application covers the ...
(Date:1/20/2019)... ... January 16, 2019 , ... uBiome, the leader ... platform that uses artificial intelligence (AI) and a data-centric approach to decentralize medicine ... ulcerative colitis. , People will Crohn’s or other chronic medical conditions join a ...
(Date:1/20/2019)... ... January 18, 2019 , ... Boston-based Laboratory as a Service ... an effort to better express its continued expansion and service offerings for biotech and ... new kind of lab: one that is more agile and adaptable than ever before. ...
Breaking Biology News(10 mins):
(Date:1/11/2019)... ... 11, 2019 , ... Drawing on over 22 years of software development expertise, ... EST will explore some of the key lessons that have driven customer satisfaction with ... multiple vendors, and find out how to ensure that you continue to be able ...
(Date:1/10/2019)... ... January 08, 2019 , ... ... spinal implant company, announced today that SAGICO will be represented at the ... annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare ...
(Date:1/8/2019)... (PRWEB) , ... January 07, 2019 , ... ... of its members into Noninvasix. This represents the second investment AngelMD has made ... mortality and morbidity, Noninvasix is developing a patient monitor to directly, accurately, and ...
(Date:1/7/2019)... ... January 07, 2019 , ... Kainos Medicine Inc. today ... drug candidate, code-named "KM-819." KM-819 is an orally active small molecule that ... South Korea. , This Phase 1 randomized, double-blind, placebo-controlled dose-escalation study was ...
Breaking Biology Technology: